Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Regeneron Pharmaceutical (REGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 53,866,712
  • Shares Outstanding, K 106,290
  • Annual Sales, $ 4,860 M
  • Annual Income, $ 895,520 K
  • 36-Month Beta 1.67
  • Price/Sales 11.08
  • Price/Cash Flow 50.45
  • Price/Book 11.07

Price Performance

See More
Period Period Low Period High Performance
1-Month
482.51 +8.00%
on 07/06/17
543.55 -4.12%
on 06/22/17
+25.80 (+5.21%)
since 06/20/17
3-Month
360.00 +44.76%
on 04/27/17
543.55 -4.12%
on 06/22/17
+144.73 (+38.45%)
since 04/20/17
52-Week
325.35 +60.18%
on 11/04/16
543.55 -4.12%
on 06/22/17
+136.43 (+35.46%)
since 07/20/16

Most Recent Stories

More News
After Yesterday's Rally of 2.68% Shares Could Potentially Pullback

Regeneron Pharm (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $509.92 to a high of $521.74. Yesterday, the shares gained 2.7%, which took the trading range above the 3-day high...

REGN : 521.13 (+2.83%)
Shares of REGN Up 25.2% Since Uptrend Call on Shares

SmarTrend identified an Uptrend for Regeneron Pharm (NASDAQ:REGN) on May 2nd, 2017 at $397.84. In approximately 3 months, Regeneron Pharm has returned 25.20% as of today's recent price of $498.11.

REGN : 521.13 (+2.83%)
Regeneron Announces the 2017 Winners of the Regeneron Prize for Creative Innovation

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the winners of the fifth annual Regeneron Prize for Creative Innovation, an award designed to recognize, reward and foster talented early-career...

REGN : 521.13 (+2.83%)
5 Top Multibagger Biotech Stocks to Buy in the 2nd Half

Draconian crackdown on drug prices easing out and likelihood of a series of buyouts will help innovation starved biotech companies to gain in the second half.

ENZ : 11.47 (-1.12%)
ALIM : 1.58 (+3.95%)
CELG : 136.31 (+0.97%)
EXAS : 39.04 (-0.26%)
SRPT : 40.93 (+20.10%)
VRTX : 159.33 (-0.23%)
REGN : 521.13 (+2.83%)
KITE : 109.89 (+4.23%)
ALXN : 129.81 (+1.97%)
Regeneron Pharm Has Returned 24.4% Since SmarTrend Recommendation (REGN)

SmarTrend identified an Uptrend for Regeneron Pharm (NASDAQ:REGN) on May 2nd, 2017 at $397.84. In approximately 2 months, Regeneron Pharm has returned 24.36% as of today's recent price of $494.77.

REGN : 521.13 (+2.83%)
Sanofi Versus AstraZeneca: Large Cap Pharma Stock Faceoff

Both stocks carry a Zacks Rank #2 (Buy).

AZN : 33.89 (+0.86%)
LLY : 84.75 (+0.62%)
REGN : 521.13 (+2.83%)
SNY : 48.06 (+2.67%)
Tech Takes the Lead...but for How Long?

Tech Takes the Lead...but for How Long?

LNG : 45.55 (-2.57%)
COP : 43.23 (-0.98%)
IYT : 170.74 (-0.97%)
RH : 76.72 (-0.88%)
VRTX : 159.33 (-0.23%)
LXFT : 64.35 (+0.47%)
REGN : 521.13 (+2.83%)
Apple's Tim Cook earns $145M in 2016, Tops S&P 500 CEOs

Apple Inc.'s (AAPL) Chief Executive Officer (CEO) Tim Cook has been declared the highest-paid CEO in the U.S., per a Bloomberg's report of take-home pay for the top 25 S&P 500 CEOs.

NFLX : 183.60 (-0.14%)
AAPL : 150.34 (-0.45%)
MCK : 165.07 (+0.13%)
ORCL : 51.13 (+0.25%)
REGN : 521.13 (+2.83%)
BioMarin Files BLA for Phenylketonuria Candidate Pegvaliase

BioMarin Pharmaceutical Inc. (BMRN) announced that it has filed a biologics license application (BLA) with the FDA for its pipeline candidate, pegvaliase for phenylketonuria (PKU).

VVUS : 1.22 (+1.67%)
BMRN : 87.74 (+0.58%)
MEIP : 3.07 (-0.32%)
REGN : 521.13 (+2.83%)
Roche (RHHBY) Launches Cobas Test for Bacterial Infections

Roche Holdings AG (RHHBY) launched CE-IVD, the cobas MRSA/SA nucleic acid test be used on the cobas Liat System for the qualitative detection and differentiation of methicillin-resistant MRSA and SA at...

BAYRY : 130.4700 (+1.51%)
VVUS : 1.22 (+1.67%)
RHHBY : 32.2000 (+0.75%)
REGN : 521.13 (+2.83%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic drugs for thetreatment of serious medical conditions. Regeneron's platform technologies include Targeted GenomicsTM, FunctionomicsTM, and Designer Protein TherapeuticsTM....

See More

Support & Resistance

2nd Resistance Point 533.62
1st Resistance Point 527.37
Last Price 521.13
1st Support Level 512.40
2nd Support Level 503.68

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.